Kendrick Bashor, MD
Family Medicine · Cuyahoga Falls, OHNPI 1457355083
Payments from drug & device makers
Across 560 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- AstraZeneca$811
- Lundbeck LLC$717
- Johnson & Johnson$704
- plus $3K from 27 others
What the payments were for
- Food & beverage$9,043100%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 74 | $1,293 |
| AbbVie(2 entities) | 68 | $1,164 |
| Otsuka America Pharmaceutical, Inc. | 59 | $1,014 |
| AstraZeneca | 45 | $811 |
| Lundbeck LLC | 41 | $717 |
| Johnson & Johnson | 42 | $704 |
| Novo Nordisk | 38 | $462 |
| Pfizer | 26 | $377 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $371 |
| Neurocrine Biosciences, Inc. | 23 | $352 |
| Teva Pharmaceuticals USA, Inc. | 24 | $327 |
| Astellas Pharma US Inc | 14 | $221 |
| Indivior Inc. | 10 | $190 |
| Amarin Pharma, Inc. | 9 | $168 |
| Vanda Pharmaceuticals Inc. | 8 | $140 |
| Bayer | 6 | $129 |
| Novartis | 8 | $118 |
| GSK | 7 | $101 |
| Lilly USA, LLC | 5 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $70 |
| Sunovion Pharmaceuticals Inc. | 4 | $52 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Gilead | 1 | $21 |
| Bausch Health US, LLC | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
| Noven Therapeutics, LLC | 1 | $11 |
How this compares
$9,079 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 152 | $144,621 |
| MounjaroTirzepatide | 108 | $116,367 |
| Spiriva RespimatTiotropium Bromide | 155 | $81,047 |
| FarxigaDapagliflozin Propanediol | 132 | $77,747 |
| EliquisApixaban | 86 | $46,873 |
| OzempicSemaglutide | 49 | $45,057 |
| RybelsusSemaglutide | 42 | $41,374 |
| MyrbetriqMirabegron | 87 | $40,468 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $31,533 |
| XareltoRivaroxaban | 47 | $29,505 |
| TradjentaLinagliptin | 56 | $29,410 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $28,316 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 59 | $25,763 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 80 | $24,094 |
| JanuviaSitagliptin Phosphate | 47 | $23,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $87 | $260,988260 claims |
| Boehringer IngelheimSpiriva Respimat, Tradjenta, Jardiance, Combivent Respimat, Stiolto Respimat | $13 | $146,627278 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere, Breztri Aerosphere, Symbicort | $811 | $131,608259 claims |
| Novo NordiskOzempic, Rybelsus | $462 | $86,43191 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Incruse Ellipta, Anoro Ellipta | $101 | $78,259194 claims |
| PfizerEliquis, Abrysvo | $377 | $70,967166 claims |
| Astellas Pharma US IncMyrbetriq | $221 | $40,46887 claims |
| Johnson & JohnsonXarelto | $704 | $29,50547 claims |
| AbbVieLinzess | $1,164 | $15,18428 claims |
| NovartisEntresto | $118 | $14,64622 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $327 | $4,19917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Cuyahoga Falls
- Tricia BedrickCuyahoga Falls$259K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.